The BioTech Stock on the Frontier of Gene Editing; Revolutionary Therapies

An innovative genetic medicines company focused on creating best-in-class gene editing therapies based on its proprietary platform, GeneTether Therapeutics Inc [Open in your browser]( [Investor Alert] [Stockhouse.com]( The BioTech Stock on the Frontier of Gene Editing; Revolutionary Therapies --------------------------------------------------------------- [Visit the company website]( [Facebook]( [Twitter]( BioTech Stock on the Frontier of Gene Editing; Revolutionary Therapies) [LinkedIn]( [Email](mailto:?subject=The BioTech Stock on the Frontier of Gene Editing; Revolutionary Therapies&body= Jon Brown, Stockhouse Gene editing may sound like science fiction, but it is a real doorway to a place where curative therapies can bring peace to many who live with rare genetic diseases. They would tell you that one of the most frightening aspects to deal with is the fear that what they're suffering with is too complex to see treatment in their lifetime, but through highly efficient insertion of DNA into the genome for gene correction, anything is possible. What is needed, is an experienced team capable of harnessing next generation technology to significantly increase the efficiency of gene editing to potentially cure serious and life-threatening genetic diseases. An innovative genetic medicines company focused on creating best-in-class gene editing therapies based on its proprietary platform, GeneTether Therapeutics Inc. ([CSE: GTTX]( [Forum]( is developing its transformative proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction. The company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases. Thanks to its proprietary method to "tether" donor DNA templates to the genome editing complex, the template is readily available for use during the genome editing repair stage. To advance and expand its platform, GeneTether Therapeutics successfully completed a proof of concept experiment, and successfully completed its initial public offering (IPO) to build its business. Let's dig a little deeper into what this company has to offer .... How it works: Like a biological "find and delete" function on your computer, a gene editing nuclease is guided to a precise, predefined location in a cell's DNA where it creates a double-strand break. GeneTether's proof of concept study demonstrated an approximately seven-times-higher gene editing efficiency as compared to the same gene editing payload without application of GeneTether's technology. By actively positioning reparative DNA fragments (referred to as donor DNA templates) near the location of double strand breaks in a cell's DNA, GeneTether's platform has the potential to significantly improve upon current gene editing methods. These double strand breaks can be created by certain types of DNA-cutting tools, including clustered, regularly interspaced, short palindromic repeats (CRISPR/Cas9). Donor DNA templates contain normal copies or fragments of the mutated, disease-causing genes of interest. By positioning a donor DNA template directly at the site of a double strand break, the GeneTether platform drives the DNA repair process towards homology-directed repair (HDR), a cellular repair mechanism that incorporates the genetic information of a DNA template, rather than the error-prone process of non-homologous end joining (NHEJ). Proof of concept: The very heart and soul of GeneTether Therapeutics is its platform technology. It is modular; therefore it has the potential to work for any organ-diseases. The company's recent proof of concept demonstrated the platform's ability to show the efficiency increasing by seven times. [SEE COMPANY PROFILE]( Initial public offering: In March 2022, GeneTether Therapeutics successfully closed its IPO and concurrent non-brokered private placement. A total of 7.5 million units were sold at a price of $0.60 per unit for aggregate gross proceeds of $4.5 million. The company's Chief Executive Officer, Roland Boivin, BCom, MBA, sat down with Dave Jackson to discuss the news. Click Image to Play Video The company's common shares commenced trading on the Canadian Securities Exchange under the symbol GTTX. Treatment beyond known limits: In its work to build a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin, the company believes that the GeneTether platform may have broad applicability and they are currently exploring other potential uses, including the treatment of genetic diseases in organs beyond the kidney and skin. The platform may also allow for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases. Since October 2021, GeneTether has been engaging in collaboration discussions with multiple genetic medicines companies. While investors often wonder if a start-up company has enough focus to bring their endeavours to fruition, this platform has a diverse array of conditions to which it is applicable. CEO Boivin noted that focus is exactly what the team has in mind over the next six months to a year. "Moving forward, we have identified some of the disease targets. What we are trying to do, is bring that focus to other aspects of the platform. We have identified diseases that we want to focus on, and we are going to move forward with additional gene editing and correction on that while we keep expanding our overall platform at the same time." Financial picture: Boasting wholly owned intellectual property, the company has no third-party financial obligations. It is not always the case that a company fully owns its IP. Before he became the company's CSO, Geoffrey Sargent said he seeded the idea that proximity matters during his time working at the Baylor College of Medicine and during some gene editing experiments that weren't working very well, he understood how this could all come together. "If you look at the genesis of a lot of start-up companies, they are often spun out of academic labs at universities. People will take what they have done in their lab, publish papers on it, they think they have a great idea, and they'll use this to spin a company out. Typically, what happens then, is that you are going to do a licensing deal with the university as you do the spin out of a company. We chose to develop the technology independently and take it straight into the company." [INVESTOR UPDATES]( Meet the team: Founded by EGB Ventures founder and managing partner, William J. Garner, M.D., GeneTether Therapeutics is built upon extensive public life science company and global capital markets experience. The team is led by CEO and Director Boivin (pictured top), backed by the company's co-founder and Chief Scientific Officer, Geoffrey Sargent, PhD (pictured above), a veteran gene editing researcher. Chief Financial Officer Jean Jen, BBA, MPAcc, CPA, CA held senior positions at Arbutus Biopharma Corp. (formerly Tekmira Pharmaceuticals Corp.), a NASDAQ-listed clinical-stage biopharma company with an expertise in liposomal drug delivery and RNA interference, where she helped in the Company's growth to $1 billion in market cap. Vice President, Research and Development Peter Sampson, BSc, MSc, PhD, came to the team from Scientus Pharma where he served as the Director of Research and Development having led the advancement of their extraction technology through to commercialization. Chairman & Co-Founder Daren Graham, BBA, JD, is currently Chief Operating Officer of EGB Ventures. Previously he was a Co-Founder of Osteon Therapeutics, Managing Director of Allele Capital Partners, Executive Director in Tribal Capital Markets' Equity Capital Life Sciences Division, and Chief Legal Officer and Vice President of Strategic Development at Sancilio Pharmaceuticals Company. The company's Scientific Advisory Board Chair, Kuldeep Neote, PhD has more than 25 years in the life science industry, including as a researcher at Genentech, Pfizer, and Eli Lilly and Company, and as a business development executive at Johnson & Johnson and Eli Lilly and Company. He is currently an Entrepreneur-in-Residence at FACIT/OICR in Toronto and at The National Institutes of Health in Maryland. Investment summary: GeneTether already has a patent issued in Australia and then in February 2022 the company received a notice of allowance from the United States Patent and Trademark Office, in addition to other jurisdictions that the company had filed in, as well. Investors take note: GeneTether Therapeutics represents an undervalued asset in the health care space that it gives opportunities for retail investors and smaller institutional investors to get in early and be part of the upside. [VIEW COMPANY WEBSITE]( FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing. --------------------------------------------------------------- [stockhouse]( Stockhouse Publishing Ltd. 1100 – 609 West Hastings Street | Vancouver | BC | V6B 4W4 | CA [Unsubscribe]( | [Manage Preferences]( [Facebook]( [Twitter]( [LinkedIn]( This email was sent to you by Stockhouse Publishing Ltd. because you consented to receive messages from us. You may manage your subscription preferences at any time. You may contact our email compliance officer at compliance@stockhouse.com The advertiser featured in this Stockhouse Publishing Ltd. Alert has paid a fee in cash not exceeding $5,000 to have their corporate information featured. The information shown is solely the responsibility of the advertiser [GeneTether Therapeutics Inc], not Stockhouse Publishing Ltd, whose only function was as a supplier of media facilities. Any information provided is not to be construed as a recommendation or suggestion or offer to buy or sell securities. Your information is shared only with the advertiser featured in this Alert and will not be sold or rented to any other third party. The advertiser may contact you from time to time with updates. You opted in to receive this Alert, which are sent on a request-only basis. To advertise, please contact us at sales@stockhouse.com.